Insmed shares jump as investors refocus on guidance and conference presentation

Insmed Incorporated (INSM) is up 6.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to renewed investor attention around Insmed’s near-term commercial outlook and pipeline narrative as management presents at a major healthcare investor conference. The stock may also be rebounding after recent volatility around its May 7, 2026 quarterly update, with traders leaning into reiterated 2026 revenue guidance and upcoming respiratory data disclosures.

Details:

Insmed management is scheduled to present at the BofA Securities 2026 Healthcare Conference on May 12, 2026, and the company highlighted access to a live webcast and its latest investor presentation.

In its May 7, 2026 quarterly release, Insmed reiterated 2026 BRINSUPRI revenue guidance of at least $1 billion and 2026 ARIKAYCE revenue guidance of $450 million to $470 million.

Insmed previously announced plans to present multiple respiratory abstracts at ATS 2026 (May 17–20), including late-breaking ARIKAYCE Phase 3b ENCORE study content, which can increase near-term catalyst interest.

This could also reflect a sentiment reset after the post-earnings selloff, with dip-buyers positioning ahead of conferences and May clinical/scientific visibility.

Sources:

Insmed Investor Relations, Nasdaq, PR Newswire

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$INSM Insider Trading Activity

$INSM insiders have traded $INSM stock on the open market 118 times in the past 6 months. Of those trades, 0 have been purchases and 118 have been sales.

Here’s a breakdown of recent trading of $INSM stock by insiders over the last 6 months:

WILLIAM LEWIS (Chair and CEO) has made 0 purchases and 58 sales selling 141,587 shares for an estimated $22,537,507.
ROGER ADSETT (Chief Operating Officer) has made 0 purchases and 7 sales selling 93,141 shares for an estimated $15,367,891.
LEO LEE has made 0 purchases and 5 sales selling 75,000 shares for an estimated $14,692,249.
MARTINA M.D. FLAMMER (Chief Medical Officer) has made 0 purchases and 29 sales selling 80,487 shares for an estimated $14,591,148.
MICHAEL ALEXANDER SMITH (Chief Legal Officer) has made 0 purchases and 8 sales selling 48,210 shares for an estimated $7,473,609.
ORLOV S NICOLE SCHAEFFER (Chief People Strategy Officer) has made 0 purchases and 4 sales selling 30,000 shares for an estimated $5,820,060.
MELVIN MD SHAROKY sold 20,000 shares for an estimated $4,100,200
ELIZABETH M ANDERSON has made 0 purchases and 2 sales selling 15,000 shares for an estimated $2,981,600.
SARA BONSTEIN (Chief Financial Officer) has made 0 purchases and 4 sales selling 5,390 shares for an estimated $925,675.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$INSM Hedge Fund Activity

We have seen 374 institutional investors add shares of $INSM stock to their portfolio, and 314 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

PRICE T ROWE ASSOCIATES INC /MD/ removed 2,892,000 shares (-41.7%) from their portfolio in Q4 2025, for an estimated $503,323,680
BLACKROCK, INC. added 2,700,148 shares (+21.8%) to their portfolio in Q4 2025, for an estimated $469,933,757
CAPITAL INTERNATIONAL INVESTORS removed 2,402,182 shares (-31.8%) from their portfolio in Q4 2025, for an estimated $418,075,755
RTW INVESTMENTS, LP added 1,758,321 shares (+57.0%) to their portfolio in Q4 2025, for an estimated $306,018,186
QUBE RESEARCH & TECHNOLOGIES LTD removed 1,544,315 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $268,772,582
D. E. SHAW & CO., INC. removed 1,306,469 shares (-23.1%) from their portfolio in Q4 2025, for an estimated $227,377,864
STATE STREET CORP added 1,217,390 shares (+30.6%) to their portfolio in Q4 2025, for an estimated $211,874,555

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$INSM Analyst Ratings

Wall Street analysts have issued reports on $INSM in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 02/23/2026
UBS issued a "Buy" rating on 01/06/2026
TD Cowen issued a "Buy" rating on 12/18/2025
Goldman Sachs issued a "Buy" rating on 12/18/2025
Wells Fargo issued a "Overweight" rating on 12/16/2025
Mizuho issued a "Outperform" rating on 12/01/2025

To track analyst ratings and price targets for $INSM, check out Quiver Quantitative's $INSM forecast page.

$INSM Price Targets

Multiple analysts have issued price targets for $INSM recently. We have seen 16 analysts offer price targets for $INSM in the last 6 months, with a median target of $215.0.

Here are some recent targets:

Benjamin Burnett from Wells Fargo set a target price of $160.0 on 05/08/2026
Vamil Divan from Guggenheim set a target price of $226.0 on 05/08/2026
Leonid Timashev from RBC Capital set a target price of $205.0 on 05/08/2026
Adam Walsh from Roth Capital set a target price of $212.0 on 04/17/2026
Eliana Merle from Barclays set a target price of $237.0 on 04/01/2026
Matthew Harrison from Morgan Stanley set a target price of $212.0 on 03/30/2026
Andrew S. Fein from HC Wainwright & Co. set a target price of $245.0 on 03/26/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.